Hepatitis C-HIV coinfection: Current and future therapy

Jagdeep J. Vyas, Robert S. Brown, Paul J. Gaglio

Research output: Contribution to journalReview articlepeer-review


Coinfection with hepatitis C in HIV-infected patients has been reported in 15-70% of patients depending on the mode of acquisition of both viruses. As recent advances in HIV-directed antiviral therapy have markedly delayed HIV progression and mortality, the incidence of complications arising from hepatitis C-associated liver disease in coinfected patients is increasing exponentially. The interaction of HIV and hepatitis C is complex. It is clear that HIV infection negatively affects the natural history of hepatitis C, while HIV-directed therapy may enhance immunologic response and exacerbate hepatocellular injury induced by hepatitis C via immune reconstitution. In this review, the pathobiology, inter-relation of hepatitis C and HIV infection in coinfected patients as well as present and future treatment in this unique patient population are discussed.

Original languageEnglish (US)
Pages (from-to)433-439
Number of pages7
JournalExpert Review of Anti-Infective Therapy
Issue number3
StatePublished - Oct 2003


  • HIV interferon
  • Helicase
  • Hepatitis C
  • Isomerase
  • Pegylated interferon
  • Protease
  • Replicase
  • Ribavirin
  • Sustained virologic response

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)
  • Virology
  • Infectious Diseases


Dive into the research topics of 'Hepatitis C-HIV coinfection: Current and future therapy'. Together they form a unique fingerprint.

Cite this